At NYU Langone’s Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders, I treat children who have pediatric malignancies, such as leukemia and lymphoma. My personal philosophy and our team’s goal is to provide individualized treatment that fits each child.
We don’t just treat patients—we care for children and their families. We use a 360-degree approach that extends beyond medical treatment, aiming to improve diet and nutrition and reduce the psychological, social, and spiritual burden of illness. The cure rate for childhood cancers has improved dramatically, but we want children and their families to continue to live their lives as healthfully as possible, so we focus on the future from the first day of treatment.
As an oncologist involved in several national committees, I have an appreciation of where oncology is headed and how it has changed. I perform research that is funded by the National Cancer Institute and focused on discovering the molecular origins of childhood cancers. I use this research to develop better treatments and, someday, preventive measures. We are also developing precision medicine, in which we use the genetic makeup of a tumor to understand its vulnerabilities.
Conditions and Treatments
Show More Conditions
- Julie and Edward J. Minskoff Professor of Pediatrics, Department of Pediatrics
- Professor, Department of Pathology
- Dir Division of Pediatric Hematology/Oncology
- Assoc Chair Clinical and Translational Research
- American Board of Pediatrics (Pediatric Hematology-Oncology), 1987
- American Board of Pediatrics - Pediatrics, 1984
Education and Training
- Fellowship, Stanford University Hospital, Hematology Oncology, 1987
- Fellowship, Stanford University Hospital, Peds Hem/Oncology, 1984
- Residency, Children's Hospital Medical Center, Pediatrics, 1982
- MD from University Of California, 1978
Locations and Appointments
- Aetna HMO
- Aetna Indemnity
- Aetna Medicare
- Aetna POS
- Aetna PPO/EPO
- Affinity Exchange- Essential
- Cigna EPO/POS
- Cigna PPO
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield HealthPlus
- Empire Blue Cross Blue Shield HealthPlus Essential
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield MediBlue
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
- Empire Blue Cross Blue Shield Pathways, Enhanced
- Fidelis Child Health
- Fidelis Essential
- Fidelis Exchange
- Fidelis Family Health
- Fidelis Medicaid
- Fidelis Medicare
- GHI CBP
- HIP Access I
- HIP Access II
- HIP Child Health
- HIP EPO/PPO
- HIP Essential
- HIP Family Health
- HIP HMO
- HIP Medicaid
- HIP Medicare
- HIP POS
- HealthSmart (WTC)
- Healthfirst Essential
- Hotel Trades
- Humana Medicare
- Local 1199 PPO
- MagnaCare PPO
- MetroPlus Child Health
- MetroPlus Essential
- MetroPlus Exchange Plans
- MetroPlus Family Health
- MetroPlus Medicaid
- MetroPlus Medicare
- MultiPlan/PHCS PPO
- NY Medicaid
- NYS Empire Plan
- Oxford Freedom
- Oxford Liberty
- Oxford Medicare
- UPN Elite
- UnitedHealthcare Community & State Plan
- UnitedHealthcare Core and Charter
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare Medicare
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
- Village Caremax
- Visiting Nurse Service (VNS) Medicare
Stephen D. Hassenfeld Childrens Center for Cancer & Blood Disorders
160 East 32nd Street, 3rd Floor
New York, NY 10016
Our laboratory is focused on two major challenges facing children with acute lymphoblastic leukemia (ALL).
First, in spite of dramatic improvements in outcome one in four children will suffer a relapse and their prognosis is poor.
Second, the "cost" of therapy for those who are cured is high with short and long term side effects. Therefore our laboratory seeks to understand mechanisms of drug resistance and to identify pathways unique to the cancer cell that can serve as targets for more effective, less toxic therapeutic approaches.
In addition we are using genomic and proteomic approaches to predict prognosis better so that therapy can be tailored to the individual patient thereby maximizing chances for cure while minimizing side effects.
We have identified gene expression profiles that predict response to therapy and are validating these signatures in an independent cohort of children currently undergoing therapy for ALL.
In addition similar efforts using expression profiling to characterize blasts at relapse has led to the provisional identification of a number of drug resistance mechanisms in ALL.
We are now using siRNA approaches to validate the functional significance of these pathways and our long term goal is to use relevant pathways as targets for therapy.
Finally we have had a long term interest in defining cell death pathways that operate in vivo and have discovered that leukemic blasts use a variety of pathways to execute apoptosis.
We hypothesize that the route of cell death correlates with response to therapy and such pathways can be modulated to favor cancer cell death thereby maximizing the therapeutic potential of conventional agents.
Our laboratory encompasses the full spectrum of investigation involving basic "bench" research, highly translational efforts using samples from patients and clinical trials in children with ALL.
Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells
Abrams, Rachel P; Carroll, William L; Woerpel, K A
ACS chemical biology. 2016 Mar 1. 11 (5): 1305-1312
Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient
Bhatla, Teena; Dandekar, Smita; Lu, Benjamin Y; Wang, Jinhua; Han, Eugenia; Bitterman, Danielle; Jones, Courtney L; Evensen, Nikki A; Magid, Margret; Meyer, Julia A; Carroll, William L
Journal of pediatric hematology/oncology. 2016 Jan . 38 (1): e21-e25
Therapies on the horizon for childhood acute lymphoblastic leukemia
Carroll, William L; Hunger, Stephen P
Current opinion in pediatrics. 2016 Feb . 28 (1): 12-18